All In Biotech

Drug Trial Radar · NCT06854458

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States Study

The Multicenter Stress Cardiac Magnetic Resonance Quantitative Perfusion Imaging in the United States (SPINS2) Study

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Jan 2029

Study completion Mar 2029

Sponsor

Lead sponsor
Brigham and Women's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research aims to investigate whether symptoms of chest pain or shortness of breath among the study population are arising due to a heart problem, particularly any reduction of blood flow to the heart muscle from blockages in the coronary blood vessels or inflammation of the heart using cardiac magnetic resonance imaging that measures the amount of blood flow during a stress state meant to simulate vigorous exercise. At present, doctors use standard magnetic resonance imaging pictures of blood flow patterns to treat heart disease. The investigators want to study if detailed blood flow measurements, in addition to the standard blood flow pattern, could diagnose heart disease more accurately and allow more doctors to understand the severity of heart disease. Early research has demonstrated that detailed blood flow measurements may be more accurate in diagnosing heart disease in some patients, but doctors need more information to know how to use these measurements.

Conditions

  • Ischemic Heart Disease (IHD)
  • Cardiac Magnetic Resonance Imaging
  • Myocardial Blood Flow

Interventions

  • Quantitative Myocardial Blood Flow EvaluationDiagnostic test

    The perfusion sequence will produce on-the-fly additional quantitative perfusion maps with segmental myocardial blood flow values.

  • Qualitative Myocardial Blood Flow EvaluationDiagnostic test

    The perfusion sequence will not produce additional quantitative perfusion maps.

  • GadavistDrug

    Participants will receive Gadavist 0.05 mmol/kg dose for each stress and rest perfusion imaging (total dose of 0.1 mmol/kg).

  • VasodilatorDrug

    All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).

  • Blood draw for the laboratory assessmentDiagnostic test

    A single (7-10 ml tube) whole blood sample will be collected from each patient for processing of blood biomarkers.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary composite outcome of major cardiovascular adverse events (MACE)Time frame: From cardiac magnetic resonance imaging to the end of follow-up in 24 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California · Recruiting

  • UofL Health - Heart Hospital

    Louisville, Kentucky · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • St. Francis Hospital and Heart Center

    Roslyn, New York · Recruiting

  • Atrium Health - Sanger Heart & Vascular Institute

    Charlotte, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Recruiting

  • The Ohio State University

    Columbus, Ohio · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • University of Virginia

    Charlottesville, Virginia · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.